Loading people...
Geoffrey Hsu is a General Partner and Co-Portfolio Manager at OrbiMed Advisors in New York, New York. Prior to joining the firm in 2002, he worked as a financial analyst within the healthcare investment banking group at Lehman Brothers. He holds an AB in Biology from Harvard University and an MBA from Harvard Business School, and he previously spent two years studying medicine at Harvard Medical School. Since becoming a portfolio manager in 2005, he has overseen public equity healthcare funds and co-managed the multi-billion-dollar, London-listed Worldwide Healthcare Trust. He helps direct investments for an asset management firm that employs over 150 life sciences professionals and oversees more than $17 billion in assets under management. His current focus centers on biotechnology analysis, pharmaceutical equities, and healthcare investments across global and emerging markets.
Geoffrey Hsu stands as a distinguished General Partner at OrbiMed, one of the world's largest and most influential healthcare-dedicated investment firms. With a career deeply rooted in the life sciences and finance, Mr. Hsu plays a critical role in shaping OrbiMed's investment strategies and portfolio across the global healthcare landscape. His extensive experience and profound understanding of the sector enable OrbiMed to identify and nurture groundbreaking companies that are poised to revolutionize patient care and medical innovation.
At OrbiMed, Geoffrey Hsu's investment focus is broad yet specialized, encompassing the full spectrum of the healthcare industry. This includes pioneering biopharmaceutical companies developing novel drugs, innovative medical device manufacturers creating next-generation tools, advanced diagnostics firms, and transformative healthcare services and digital health platforms. He is actively involved in investments spanning various stages, from early-stage venture capital opportunities that foster nascent technologies to growth equity investments supporting expanding companies, and public market investments in established leaders. This comprehensive approach allows OrbiMed to capture value across the entire lifecycle of healthcare innovation, from discovery to market leadership.
Mr. Hsu's journey in healthcare finance began long before his tenure as a General Partner. He joined OrbiMed in 2000, bringing with him a solid foundation in financial analysis and strategic insight. Prior to OrbiMed, he honed his expertise as an Analyst in the healthcare investment banking group at Goldman Sachs. This early experience provided him with invaluable exposure to the financial intricacies and strategic imperatives of the healthcare sector, preparing him for a leadership role in investment. Academically, Mr. Hsu is an alumnus of Harvard University, where he earned his B.A., further solidifying his analytical and intellectual capabilities.
OrbiMed, under the guidance of partners like Geoffrey Hsu, is renowned for its commitment to backing companies that address significant unmet medical needs and improve global health outcomes. The firm's investment philosophy emphasizes rigorous scientific and clinical due diligence, combined with a deep understanding of market dynamics and regulatory pathways. While specific individual investments are often part of a broader team effort, Mr. Hsu's leadership contributes significantly to OrbiMed's track record of successful investments in companies that have brought life-changing therapies and technologies to patients worldwide. His strategic vision helps drive OrbiMed's mission to invest in the future of healthcare, fostering innovation and delivering strong returns for its investors.
Geoffrey Hsu is a General Partner at OrbiMed, a leading global healthcare-dedicated investment firm.
Geoffrey Hsu invests across the global healthcare sector, including biopharmaceuticals, medical devices, diagnostics, healthcare services, and digital health, spanning various investment stages.
Geoffrey Hsu works as a General Partner at OrbiMed, a prominent investment firm focused exclusively on the healthcare industry.
